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1088-120 Left Ventricle Systolic Dysfunction, Total Mortality, and 
Sudden Death in Patients With Myocardial Infarction 
Treated With N-3 Polyunsaturated Fatty Acids
Alejandro Macchia, Aldo Pietro Maggioni, Maria Grazia Franzosi, Luigi Tavazzi, Gianni 
Tognoni, Franco Valagussa, Roberto Marchioli, The GISSI Prevenzione Investigators, 
Consorzio Mario Negri Sud, Santa Maria Imbaro, Italy
Background: Severe left ventricular systolic dysfunction (LVSD) after myocardial infarc-
tion (MI) increases the risk of heart failure, mortality (M) and sudden death (SD). Several
treatments reduce M and SD in this cohort. Less information is available on the associa-
tion between mild/moderate LVSD, M and particularly SD. N-3 polyunsaturated fatty acids
(n-3) reduced M and SD in post-MI, but the effect in patient with LVSD is unknown.
Methods: We selected 9351 post-MI patients from the GISSI-Prevenzione trial who had a
measurement of ejection fraction (EF). LVSD was classified as absent, EF > 50%; mild,
EF 46-50%; moderate, EF 41-45%;severe, EF< 40%. Cox regression models adjusted
for prognostic indicators were fitted.
Results: As compared with patients without LVSD, the 46% with LVSD had higher rates of
M and SD (12.3% vs 5.8%% and 3.4% vs 1.3%). There was a graded association
between LVSD, M and SD. Treatment with n-3 reduced M as well as SD in patients with
and without LVSD (heterogenity test NS). When we assessed the effect of n-3 on SD
according to the grade of LVSD, the test for trend was statistically significant thus indicat-
ing a concentrated effect of n-3 in patients with progressively worsening of LV systolic
function.
Conclusions: mild/moderate LVSD is a common feature of post-MI patients and is associ-
ated with increased risk of M and SD. Treatment with n-3 decreased M and SD in patients
with and without LVSD. Progressively increasing LVSD is associated with elevated risk of
SD and with increased benefit from n-3
1088-121 Improved Myocardial High-Energy Phosphate 
Metabolism Induces by Partial Free Fatty Acid Inhibition 
in Patients With Heart Failure
Gabriele Fragasso, Francesco De Cobelli, Gianluca Perseghin, Antonio Esposito, Altin 
Palloshi, Giorgio Bassanelli, Chiara Montano, Alessandro Del Maschio, Alberto 
Margonato, Istituto Scientifico/Universita' San Raffaele, Milano, Italy
Background. The addition of the partial free-fatty acid inhibitor trimetazidine to standard
treatment, has beenshown to effectively improve left ventricular function in patients (pts)
with heart failure. The beneficial effect of trimetazidine has been attributed to preserva-
tion of cardiac phosphocreatine (PCr) and adenosine triphosphate (ATP) intracellular lev-
els. Aim of this study was to assess the effects of trimetazidine on PCr and ATP
concentrations in pts with heart failure.
Methods. Twelve pts (1 female) with heart failure (6 post-ischemic, 5 hypertensive, 1
dilated cardiomyopathy) on conventional therapy were randomised in a double blind,
cross-over study to placebo or trimetazidine (20mg t.i.d) for 2 periods of 90 days At the
end of each period, all pts underwent exercise testing, 2D-echocardiography and cine
magnetic resonance imaging and spectroscopy (MRS). NYHA class, ejection fraction
(EF), maximal rate-pressure product (RPP) and METS were evaluated. Concentrations
of PCr and ATP were determined by 31P-MRS with spatial localization with optimum
pointspread function.
Results. On trimetazidine, NYHA class decreased from 3.1±0.2 to 2.5±0.5 (p=0.009)
while exercise time (from 323±148 to 334±156 sec, p=0.36), peak RPP (from
17462±3601 to 18894±4893 mmHgxbpm, p=0.09), METS (from 7.44±1.84 to 8.78±2.72,
p=0.034) and EF (34±10 vs 39±10%, p=0.037) increased. The mean cardiac PCr/ATP
ratio was 1.36±0.35 with placebo but was increased by 19% to 1.62±0.45 (P=0.04) with
trimetazidine.
Conclusions. In conclusion, trimetazidine improves left ventricular function and symp-
toms in pts with heart failure. These beneficial effects are likely related to the observed
trimetazidine-induced improvement of cardiac high-energy phosphate metabolism. Meta-
bolic modulation with partial fatty acid inhibitors can represent a new therapeutic comple-
ment in heart failure and should be tested in large scale trials.
1088-122 Augmentation of Glucose Metabolism With Perhexiline 
Improves Maximal Oxygen Consumption and Quality of 
Life in Patients With Nonischaemic Dilated 
Cardiomyopathy
Leong Lee, Ross Campbell, Rachel Field, Prasad Gunaruwan, Justin Taylor, Matthias 
Schmitt, John Horowitz, Michael Frenneaux, Wales Heart Research Institute, Cardiff, 
United Kingdom
Background
Despite considerable advances in pharmacotherapy, chronic heart failure (CHF) remains
a major cause of morbidity and mortality. Additional effective therapies are needed. Glu-
cose metabolism is more oxygen efficient than Free Fatty Acids (FFA) metabolism at
generating ATP. CHF leads to a shift in metabolic substrate use from FFA to glucose but
whether this represents an adaptive or maladaptive process is unclear. The anti-anginal
drug perhexiline further augments glucose metabolism by inhibiting mitochondrial FFA
uptake. We hypothesize that augmentation of glucose metabolism is beneficial in CHF
and associated with an improvement in symptoms, and peak exercise oxygen consump-
tion (VO2 max), an important measure of both prognosis and functional status.
Methods
This was a randomised double blind placebo controlled trial. 24 patients with Dilated Car-
diomyopathy, angiographically normal coronary arteries, and optimally medicated CHF
(NYHA II-III, EF<40%) were randomised to perhexiline (n=12) or placebo (n=12) for 2
months. Cardiopulmonary exercise testing with respiratory gas analysis and completion
of the Minnesota Living with Heart Failure Questionnaire (MLHFQ) were performed
before and after treatment.
Results
Expressed as mean ± SEM. VO2max was similar at baseline in the perhexiline and pla-
cebo groups (17.1 ± 1.1 vs. 16.0 ± 1.3 mls/kg/min). Following treatment, VO2max was
unchanged in the placebo group (16.1 ± 1.5 mls/kg/min) but increased in the perhexiline
group (19.6 ± 1.5 mls/kg/min). ANCOVA using baseline values as covariates demon-
strated a significant effect of perhexiline vs. placebo on VO2max; p=0.03. MLHFQ scores
were similar at baseline in the perhexiline and placebo groups (45.4 ± 7.9 vs. 47.2 ± 6.5
respectively) and fell markedly following treatment in the perhexiline group (30.7 ± 6.9)
but not in the placebo group (42.8 ± 6.5); ANCOVA, p=0.03.
Conclusion
Treatment with perhexiline leads to an improvement in VO2max and quality of life in
Dilated Cardiomyopathy. This benefit suggests that augmentation of glucose metabolism
could be beneficial in heart failure even in the absence of underlying ischaemia and rep-
resents a potential future treatment strategy.
1088-123 Cancion Cardiac Recovery System: Hemodynamic and 
Renal Effects
Michael R. Zile, Ron Oren, Adrian Van Bakel, Paul Mohacsi, Michael Bohm, Bernd 
Hammer, Sinisa Gradinac, Jerzy Sadowski, Krzysztof Bartus, Andre Wasler, Marvin A. 
Konstam, Medical University of South Carolina, Charleston, SC
Background: The purpose of this study was to examine the hemodynamic effects of the
Cancion Cardiac Recovery System (CRS), a novel extracorporeal device that superim-
poses continuous aortic flow on existing pulsatile flow. We hypothesized that by reducing
LV afterload and increasing aortic flow the CRS would improve the hemodynamics in
patients with acutely decompensated chronic heart failure who were refractory to stan-
dard medical therapy. Methods: The inflow to the CRS centrifugal pump was via a percu-
taneous femoral arterial cannula and outflow was via either a graft cannula anastomosed
to the left axillary artery (n=4) or percutaneously through the femoral artery (n=3) via an
aortic pigtail cannula. Results: Seven patients were placed on the CRS and supported
for an average of 66 hours (24 hrs to 5 days) with pump flows between 1.2 and 1.5
(mean, 1.3) l/min. Hemodynamic data are shown in the Figure. Data during and after
CRS suggest that the PCWP vs CI relationship is reset.Conclusions: The Cancion CRS,
a novel form of cardiac assistance, acting through a low-flow, continuous aortic flow loop,
markedly improved PCWP, CI and renal function in patients with refractory heart failure.
Hemodynamic and renal functional improvement persisted following discontinuation of
the CRS. These results suggest that the CRS may be an effective treatment for decom-
pensated chronic heart failure.
